| Jiang, Wei |
NCT06492460: 2 Courses of Concurrent Cisplatin Chemoradiotherapy After Surgery for High-risk Head and Neck Squamous Cell Carcinoma |
|
|
| Recruiting | 3 | 422 | RoW | Drug：Cisplatin, CDDP Drug | Sun Yat-sen University, Hunan Cancer Hospital, Guilin Medical University, China, Jiangsu Cancer Institute & Hospital, Xiangya Hospital of Central South University | Squamous Cell Carcinoma of Head and Neck | 09/29 | 07/33 | | |
NCT05527470: Induction Chemotherapy Followed by IMRT or Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma |
|
|
| Recruiting | 3 | 440 | RoW | Gemcitabine,Cisplatin, Induction chemotherapy regimen, Intensity-modulated radiation therapy (IMRT), Cisplatin, Concurrent chemotherapy regimen | Wei Jiang, Wuzhou Red Cross Hospital, Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Lingshan people's Hospital, Laibin People's Hospital, Nationalities Hospital of Guangxi Zhuang Autonomous Region | Nasopharyngeal Carcinoma | 11/25 | 11/27 | | |
NCT04515602: Stratified Evaluation of PDS and NACT-IDS in Ovarian Cancer (FOCUS) |
|
|
| Not yet recruiting | 3 | 410 | RoW | Primary debulking surgery, PDS, Neoadjuvant chemotherapy, Neoadjuvant chemotherapy followed by interval debulking surgery, NACT-IDS, PARPi | Shanghai Gynecologic Oncology Group, Obstetrics & Gynecology Hospital of Fudan University, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai First Maternity and Infant Hospital | Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma | 01/28 | 01/28 | | |
| Recruiting | 2 | 30 | RoW | Niraparib | Tianjin Huanhu Hospital | Recurrent Glioblastoma | 01/22 | 01/23 | | |
NCT04600817: A Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients With Newly Diagnosed Glioblastoma Who Completed Standard Concurrent Chemoradiotherapy (CCRT) |
|
|
| Active, not recruiting | 2 | 160 | RoW | TJ107, TJ107 placebo | TJ Biopharma Co., Ltd. | Newly Diagnosed Glioblastoma | 12/24 | 12/24 | | |
NCT05068427: Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced NSCLC. |
|
|
| Completed | 2 | 34 | RoW | Chidamide, CS055, Envafolimab, KN035 | Chipscreen Biosciences, Ltd. | Non Small Cell Lung Cancer | 02/23 | 05/24 | | |
| Recruiting | 2 | 200 | RoW | Camrelizumab, PD-1 antibody, Gemcitabine, Gem, Induction Cisplatin, DDP, intensity-modulated radiotherapy, IMRT, Concurrent cisplatin | Wei Jiang, Wuzhou Red Cross Hospital, Guangxi Nanxishan Hospital, Laibin People's Hospital, Lingshan people's Hospital | Nasopharyngeal Carcinoma | 04/25 | 04/26 | | |
| Recruiting | 2 | 167 | RoW | Surgery, secondary cytoreduction, carboplatin/taxane, carboplatin/gemcitabine, cisplatin/gemcitabine, liposome doxorubicin/carboplatin..., third-line therapy, Niraparib, maintenance therapy | Shanghai Gynecologic Oncology Group, Fudan University, Shanghai Jiao Tong University School of Medicine, Zhejiang Cancer Hospital, Sun Yat-sen University | Ovarian Cancer Recurrent, Fallopian Tube Cancer, Primary Peritoneal Carcinoma | 06/25 | 12/26 | | |
NCT06536400: Phase I Study of HSK42360 in Solid Tumors With BRAF V600 Mutation |
|
|
| Recruiting | 1 | 316 | RoW | HSK42360 | Haisco Pharmaceutical Group Co., Ltd. | Solid Tumors | 08/26 | 07/27 | | |
NCT03131427: China Registry for Genetic / Metabolic Liver Diseases |
|
|
| Recruiting | N/A | 20000 | RoW | Standard of care | Beijing Friendship Hospital, Beijing YouAn Hospital, Henan Provincial People's Hospital, Beijing Ditan Hospital, Hebei Medical University Third Hospital, Peking University First Hospital, Xinjiang Uygur Autonomous Region Traditional Chinese Medicine Hospital, Nanfang Hospital of Southern Medical University, Logistics University of Chinese People's Armed Police Forces, Beijing Anzhen Hospital, West China Second University Hospital of Sichuan University, Jinshan Hospital Fudan University, Fudan University | Genetic/Metabolic Liver Diseases | 04/22 | 04/27 | | |
BESMILE-HF, NCT03180320: Baduanjin-eight-silken-movement With Self-efficacy Building for Patients With Chronic Heart Failure ( Study) |
|
|
| Recruiting | N/A | 150 | RoW | BESMILE-HF program, Usual medications | Guangdong Provincial Hospital of Traditional Chinese Medicine | Heart Failure NYHA Class II, Heart Failure NYHA Class III | 12/22 | 12/22 | | |
NCT05176821: Eradication Efficacy and Safety of Two Rescue Treatments for Helicobacter Pylori Infection |
|
|
| Recruiting | N/A | 186 | RoW | esomeprazole plus amoxicillin, HDDT, amoxicillin, furazolidone, bismuth potassium citrate , esomeprazole, FT | Shanghai Zhongshan Hospital | H. Pylori Infection | 12/22 | 12/22 | | |
GIANT, NCT04765592: Guo's Aortic Arch Reconstruction :The Prospective ,Multiple Center Study About the Safety and Efficacy of WeFlow-Arch Modeler Embedded Branch Stent Graft System ( Study) |
|
|
| Active, not recruiting | N/A | 88 | RoW | WeFlow-Arch Modeler Embedded Branch Stent Graft System | Hangzhou Endonom Medtech Co., Ltd. | Aortic Arch Aneurysm | 02/25 | 02/29 | | |
NCT06327126: Efficacy and Safety of Single-session Endoscopic Stone Extraction |
|
|
| Completed | N/A | 563 | RoW | two-session ERCP, single-session ERCP | Beijing Friendship Hospital | Choledocholithiasis With Acute Cholangitis | 05/24 | 07/24 | | |
NCT06349954: Effectiveness and Safety of Single-session Endoscopic Stone Extraction |
|
|
| Recruiting | N/A | 64 | RoW | single-session ERCP, two-session ERCP | Beijing Friendship Hospital | Choledocholithiasis With Acute Cholangitis | 12/24 | 12/24 | | |
| Recruiting | N/A | 240 | RoW | Carvedilol 12.5 MG, Nucleos(t)ide Analogues | Beijing Friendship Hospital | Liver Cirrhosis, Portal Hypertension | 10/24 | 10/24 | | |
| Chen, Jie |
NCT05182463: Peginterferon Treatment Study for Inactive Chronic Hepatitis B Patients |
|
|
| Recruiting | 4 | 5000 | RoW | Peginterferon Alfa-2B, Nucleoside Analogs | Third Affiliated Hospital, Sun Yat-Sen University | Hepatitis B, Chronic | 12/26 | 11/29 | | |
NCT05830500: Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma |
|
|
| Recruiting | 4 | 360 | RoW | Anlotinib Hydrochloride Capsule | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Medullary Thyroid Cancer | 06/27 | 12/28 | | |
| Active, not recruiting | 3 | 291 | Europe, Canada, Japan, US, RoW | Selpercatinib, LY3527723, LOXO-292, Cabozantinib, Vandetanib | Loxo Oncology, Inc., Eli Lilly and Company | Medullary Thyroid Cancer | 05/23 | 02/26 | | |
COMPOSE, NCT04919226 / 2021-001086-20: Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - |
|
|
| Recruiting | 3 | 250 | Europe, US, RoW | 177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT, 177Lu-DOTATOC 177Lu-Edo, CAPTEM (Capecitabine and Temozolomide), Amino-Acid Solution, Arginine-Lysine Solution, Everolimus, FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin) | ITM Solucin GmbH | Neuroendocrine Tumors | 06/27 | 09/27 | | |
NCT06616532: PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 404 | RoW | PM8002, Paclitaxel, Topotecan | Biotheus Inc. | SCLC | 01/27 | 12/28 | | |
| Recruiting | 3 | 120 | Europe, Canada, Japan, US, RoW | Vedolizumab IV, ENTYVIO, KYNTELES, MLN0002 | Takeda, Takeda Development Center Americas, Inc. | Crohn's Disease (CD) | 11/24 | 11/24 | | |
| Active, not recruiting | 3 | 121 | Europe, Canada, Japan, US, RoW | Vedolizumab, MLN0002, ENTYVIO, KYNTELES | Takeda, Takeda Development Center Americas, Inc. | Colitis, Ulcerative | 08/25 | 08/25 | | |
| Recruiting | 3 | 240 | Europe, Canada, Japan, US, RoW | Vedolizumab IV, MLN0002, ENTYVIO, KYNTELES, No Intervention | Takeda, Takeda Development Center Americas, Inc. | Ulcerative Colitis, Crohn's Disease | 08/31 | 08/31 | | |
NCT06398444: A Clinical Study to Evaluate the Safety and Efficacy of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms |
|
|
| Not yet recruiting | 2/3 | 74 | RoW | Lutetium[177Lu] Oxodotreotide Injection | Sinotau Pharmaceutical Group | Advanced Neuroendocrine Neoplasm | 06/27 | 06/29 | | |
NCT05084677: Toripalimab Combined With Concurrent Chemoradiotherapy in Cervical Cancer |
|
|
| Recruiting | 2 | 96 | RoW | Toripalimab Combined With Concurrent Platinum-based Chemoradiotherapy | Tianjin Medical University Cancer Institute and Hospital | Cervical Cancer | 12/22 | 12/24 | | |
NCT05033132: A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical Cancer |
|
|
| Withdrawn | 2 | 177 | RoW | Balstilimab, Balstilimab + Zalifrelimab | Agenus Inc., Betta Pharmaceuticals Co., Ltd. | Cervical Cancer | 12/24 | 12/24 | | |
NCT06093438: Induction Toripalimab and Chemotherapy in Locally Advanced Cervical Cancer |
|
|
| Recruiting | 2 | 20 | RoW | Toripalimab | Tianjin Medical University Cancer Institute and Hospital | Cervical Cancer, Induction Chemotherapy, Immunotherapy | 07/25 | 07/26 | | |
NCT04893759: A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine Tumors |
|
|
| Recruiting | 1 | 60 | RoW | Pelcitoclax, APG-1252 | Ascentage Pharma Group Inc. | Neuroendocrine Tumors | 06/24 | 06/25 | | |
NCT04741373: Study on Pulmonary Rehabilitation for Stable Chronic Obstructive Pulmonary Disease(COPD) Patients |
|
|
| Recruiting | N/A | 90 | RoW | oral nutritional supplements, rehabilitation exercise, health education | Fudan University | Nutritional Support, Aerobic Exercise, Respiratory Function Tests, Body Composition, Muscle Strength | 06/21 | 09/21 | | |
NCT05176821: Eradication Efficacy and Safety of Two Rescue Treatments for Helicobacter Pylori Infection |
|
|
| Recruiting | N/A | 186 | RoW | esomeprazole plus amoxicillin, HDDT, amoxicillin, furazolidone, bismuth potassium citrate , esomeprazole, FT | Shanghai Zhongshan Hospital | H. Pylori Infection | 12/22 | 12/22 | | |
NCT06461611: Effect of Health Diary on Self-management in Adolescent Patients With Fixed Orthodontic Appliance |
|
|
| Recruiting | N/A | 140 | RoW | Health Diary Program, Traditional Health Education | Wei XIA, PhD | Oral Hygiene, Self-Management | 03/25 | 07/25 | | |
NCT06384001: Meditation for Older Adults With Chronic Low Back Pain |
|
|
| Recruiting | N/A | 66 | US | Active MBM, Sham MBM | Florida State University | Chronic Low Back Pain | 10/25 | 10/25 | | |
| Active, not recruiting | N/A | 51 | RoW | MitraClip procedure | Abbott Medical Devices | Mitral Regurgitation | 05/24 | 05/25 | | |
NCT04995159: Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVasâ„¢ BRS System |
|
|
| Not yet recruiting | N/A | 2150 | RoW | Single anti-platelet therapy, SAPT strategy, Dual anti-platelet therapy, DAPT strategy | Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Heart Disease | 01/26 | 01/28 | | |
NCT05086536: Re-compensation and Its Clinical Characteristics in HBV Decompensated Cirrhosis |
|
|
| Not yet recruiting | N/A | 600 | RoW | no intervention | Beijing Friendship Hospital, Beijing YouAn Hospital, Shandong Provincial Hospital, The Affiliated Hospital of Qingdao University, The First Affiliated Hospital of Shanxi Medical University, Xiangya Hospital of Central South University, The Second Affiliated Hospital of Baotou Medical College | Hepatitis B, Decompensated Cirrhosis | 06/22 | 12/22 | | |
MIES-BCNAT, NCT04661436: Multimodal Imaging Evaluation System of Axillary Lymph Node Staging and Treatment Strategy for Breast Cancer Neoadjuvant Therapy |
|
|
| Not yet recruiting | N/A | 300 | NA | Contrast-Enhanced Ultrasound, Magnetic Resonance Imaging | Sichuan Provincial People's Hospital | Breast Cancer | 12/22 | 12/23 | | |
NCT04830826: A Real-world Study of Adjuvant Therapy in Early Stage NSCLC With EGFR Mutation-Positive in China |
|
|
| Recruiting | N/A | 2000 | RoW | Surgeries | The First Affiliated Hospital of Guangzhou Medical University | NSCLC, Stage I, NSCLC, Stage II, NSCLC, Stage III | 01/24 | 07/24 | | |
